| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 3,047 | - | ||
| Other receivables | 153 | - | ||
| Prepaid expenses and other current assets | 179 | - | ||
| Total current assets | 3,379 | - | ||
| Property and equipment, net | 92 | - | ||
| Right-of-use assets - operating leases | 541 | - | ||
| Goodwill | 2,044 | - | ||
| Other assets | 116 | - | ||
| Total assets | 6,172 | 7,584 | ||
| Accounts payable | 958 | 1,319 | ||
| Accrued expenses | 859 | 938 | ||
| Income taxes payable | 17 | 11 | ||
| Operating lease liabilities, current | 206 | 217 | ||
| Contingent consideration liability, current | 41 | 41 | ||
| Other current liabilities | 63 | 125 | ||
| Total current liabilities | 2,144 | 2,651 | ||
| Operating lease liabilities, non-current | 346 | 376 | ||
| Warrant liabilities | - | 0 | ||
| Contingent consideration liability, non-current | - | 0 | ||
| Other liabilities | 112 | 113 | ||
| Total liabilities | 2,602 | 3,140 | ||
| Preferred stock, 0.005 par value, 1,000 shares authorized, 156 designated and outstanding of series a convertible preferred stock at september 30, 2025 and december 31, 2024, 156 liquidation preference | 1 | 1 | ||
| Common stock, 0.005 par value, 150,000 and 100,000 shares authorized at september 30, 2025 and december 31, 2024, respectively, 7,849 and 3,426 issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 39 | 37 | ||
| Additional paid-in capital | 247,656 | 247,291 | ||
| Accumulated deficit | -244,126 | -242,885 | ||
| Total stockholders equity | 3,570 | 4,444 | ||
| Total liabilities and stockholders equity | 6,172 | 7,584 | ||
Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc. (ERNA)